LinkedIN
twitter

Events

The Future of Innovation in Esophageal Diseases

EVENT

Satisfai Health sponsored and Satisfai Health CEO and Founder Dr. Michael Byrne, VP, Medical Affairs Dr. Nasim Parsa, and VP Business Development Ben Brzezynski participated in “The Future of Innovation in Esophageal Diseases”: From GERD to Esophageal Cancer event at DDW 2023.  Hosted by Northwestern Medicine Division of Gastroenterology and Esophageal Cancer Awareness Network (ECAN), the event assembled physician and industry experts and stakeholders to discuss the current state of innovation in esophageal diseases and gaps that need to be addressed in Innovation Thinktank panel discussions. 

“Having the who’s who from academia and industry in one room created great collaborative opportunities for this very important disease state. We strongly believe that Artificial Intelligence will play a key role in improving the management of Esophageal Cancer. Congratulations to Mindy Mintz Mordecai and Sri Komanduri for putting this incredible event together.” – Dr Michael Byrne 

 

 

Future of Innovation in Esophageal Diseases

Date: May 6 2023

Learn More

DDW 2023: AI models for Barrett’s & early esophageal cancer

EVENT

Satisfai Health Scientific Advisor & Director of Upper GI Cancers Helmut Messmann and Advisor Jason Samarasena MD presented AI in BE Neoplasia Detection: The New Normal or Panacea at a Breakfast Connections session on May 7, 2023  at DDW 2023.

“Excellent Barretts AI session with experts, Helmut Messmann & Jason Samarasena presenting our latest AI models with real time expert level performance for detection, delineation & differentiation of dysplastic Barrett’s & early esophageal cancer.”  – Nasim Parsa, VP Medical Affairs.

Date: May 7, 2023

Learn More

DDW 2023 ASGE Meeting "The Environmental Challenges of Endoscopy"

EVENT

Satisfai Health  VP of Medical Affairs Nasim Parsa MD, co-moderated ASGE Meeting “The Environmental Challenges of Endoscopy” with Lyndon V Hernandez on May 8, 2023 at Disease Week® (DDW) in Chicago.

Nasim reports, “AI can help reduce the carbon footprint in GI endoscopy. It was great sharing the podium with Heiko Pohl, David Armstrong, Adam Silvka, Bu’Hussain Hayee, & Swapna Gayam.”

 

 

Date: May 8, 2023

Learn More

DDW 2023 WEO Plenary Meeting: Novel applications of CADx

EVENT

Satisfai Health VP medical affairs Dr. Nasim Parsa presented the novel applications of CADx to arbitrate between discordant endoscopic & pathologic diagnosis in a World Endoscopy Organization (WEO) plenary meeting with session chairs Roupen Djinbachian and Daniel von Renteln  at DDW 2023 in Chicago. 

Nisam noted, “Endoscopist+CADx beats pathology’s accuracy for diminutive polyps in most scenarios”.

 

VP medical affairs Dr. Nasim Parsa presents on the novel applications of CADx DDW 2023

Date: May 5, 2023

Learn More

Digestive Disease Week (DDW) 2023

EVENT

Satisfai Health Chairman & CEO Dr. Michael Byrne, CFO & Director Murray Flanigan, VP of Medical Affairs Nasim Parsa MD, Chief Strategy Officer Solveig Johannessen, and VP of Business Development Ben Brzezinski  attended Digestive Disease Week® (DDW) in Chicago from May 6-9, 2023.

With 10,000 physicians, researchers and academics in attendance, DDW is the world’s premier meeting in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

 

DDW 2023 Group Photo

Date: May 6 – 9,22, 2023

Learn More

Mayo Clinic Women in Gastroenterology & Heptatology Showcase

EVENT

Women in Gastroenterology & Hepatology Showcase Nasim Parsa MD, VP of Medical Affairs at Satisfai Health, will present “Artificial Intelligence in Clinical Medicine: A True Change or a Trend!” on September 22, 2023 at the Mayo Clinic Women in Gastroenterology & Hepatology Showcase. Her presentation is part of the AI session “Artificial Intelligence (AI) and My Future Practice: The Crystal Ball Ultimate Guide”. The event is a digital symposium delivered entirely by women of national and international recognition in the fields of gastroenterology and hepatology.

Date: September 22, 2023, Virtual

Learn More

International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Annual General Meeting

EVENT

The IOIBD is dedicated to the promotion of the health people with IBD worldwide by setting the direction for patient care, education and research.

Satisfai Health is proud to be a member of the IOIBD and join in its mission.  We were happy to attend and act as a corporate sponsor for the past AGM held in Cambridge, UK on March 23, 2023. 

Date: Mar 23, 2023, Cambridge, UK

Learn More

AGA Tech Summit 2023: Focused on Adoption of Innovative GI Technology

EVENT

The 2023 AGA Tech Summit is the only event focused on fostering the development and adoption of GI technology. The Summit is where GI innovators, entrepreneurs, clinicians, medical technology companies, venture capitalists and regulatory agencies meet to identify opportunities in licensing, partnerships, and investment. Dr. Michael Byrne was pleased to be a moderator in a session on AI in Endoscopy along with other global names in AI.

Date: Mar 9 – 10, 2023, San Francisco

Learn More

AGA Tech Summit 2023: Focused on Adoption of Innovative GI Technology

EVENT

The 2023 AGA Tech Summit is the only event focused on fostering the development and adoption of GI technology. The Summit is where GI innovators, entrepreneurs, clinicians, medical technology companies, venture capitalists and regulatory agencies meet to identify opportunities in licensing, partnerships, and investment. Dr. Michael Byrne is pleased to be a moderator in a session on AI in Endoscopy along with other global names in AI.

Date: Mar 9 – 10, 2023, San Francisco

Learn More

ECCO 2023: European Crohn's & Colitis Congress

EVENT

ECCO is the largest forum for specialists in inflammatory bowel disease globally . 

Satisfai Health will be attending the conference to discuss how AI solutions delivery real-time analysis of medical imagery and provide clinicians with real-time decision support intelligence.

 

Date: Mar 1 – 4, 2023, Copenhagen

Learn More
Categories
satisfai logo

1050 Homer Street, Suite 390, Vancouver, BC V6B 2W9, Canada | 1-888-777-0661 | [email protected]

©2023 Satisfai Health, Inc

LinkedIN
twitter

Request a Demo

Dr. Reno Panaccione

Director of IBD

Dr. Panaccione is currently a Professor of Medicine, the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary and Director of Gastroenterology Research.

Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993. He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario and is certified as a fellow of the Royal College of Physicians and Surgeons of Canada in both Internal Medicine and Gastroenterology. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota. He joined the faculty of Medicine at the University of Calgary in 1999. He is an internationally recognized expert in inflammatory bowel disease. He has lectured nationally and internationally on various topics in inflammatory bowel disease and has delivered over 200 lectures in the last five years.

He is the author of many peer-reviewed articles (~250) and book chapters (25) on inflammatory bowel disease. His special interest lies in the fields of advanced therapies, biological therapy, and delivery of care through the implementation of clinical trials. He is a recognized authority on the use of biologics and has co-authored numerous guidelines on the management of inflammatory bowel disease for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn’s disease and ulcerative colitis. He has published in and reviews for prestigious journals including NEJM, Lancet, Gastroenterology and Gut. He sits on the editorial board of Inflammatory Bowel Diseases, JCC, APT, and the Canadian Journal of Gastroenterology.

He is presently the medical director for the Crohn’s and Colitis Canada (CCC) Calgary Chapter and sits on the Medical Advisory council for the Crohn’s and Colitis Foundation of Canada. He is the national chair of the CCC scholarship program. He has been awarded the highest honour, the Finkelstein award by Crohn’s and Colitis Canada for his work in the field of IBD. He is also an elected member of the International Organization of Inflammatory Bowel Disease (IOIBD) reflecting his status in the area. He was awarded the CAG Visiting Professor Award in 2016 for his contribution o the field of Gastroenterology in Canada. He is ranked amongst the top ten experts in the field worldwide (www.expertscape.com). He presently holds a senior leadership position within Alberta Health Services as the Medical Lead for Systems Integration with the mandate of improving the efficiency and quality of care that is delivered to patients.

Dr. Douglas Rex

Director of Colorectal Cancer

Dr. Douglas K. Rex is Distinguished Professor of Medicine at Indiana University School of Medicine, Chancellor’s Professor at Indiana University Purdue University Indianapolis, and Director of Endoscopy at Indiana University Hospital in Indianapolis. He graduated from Harvard College, Summa Cum Laude in 1976 and with highest distinction from Indiana University School of Medicine in 1980. He served as Chief Medical Resident at Indiana University Hospital and joined the faculty at Indiana University in 1985. He received the Outstanding Teacher Award in the Introduction to Medicine course five times and has been awarded the Indiana University School of Medicine Outstanding Teacher Award as well as Department of Medicine’s Excellence in Teaching Award. He is a full-time clinical gastroenterologist at Indiana University Hospital.

His major research interests have been in colorectal disease and, in particular, colorectal cancer screening and the technical performance of colonoscopy. He co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer. He also authored the recommendations on quality in colonoscopy of the U.S. Multi-Society Task Force on Colorectal Cancer and the American College of Gastroenterology/American Society of Gastrointestinal Endoscopy. He has authored more than 200 original research papers, 55 book chapters, 200 invited papers, 40 editorials, and 40 guideline papers. He is an Associate Editor of Journal Watch Gastroenterology and serves on the editorial boards of 11 gastroenterology journals.

He is the current chair of the U.S. Multi-Society (ACG, ASGE, AGA, ACP-ASIM) Task Force on Colorectal Cancer. He has also served in the American College of Gastroenterology as Chairman of the Board of Governors and is a Past President of the ACG. He is a member of the Governing Board of ASGE and a recipient of the Rudolph V. Schindler Award from ASGE.

Dr. Michael Byrne

CEO & Founder

Dr. Michael Byrne provides senior leadership and clinical expertise to Satisfai Health and is a clinical innovator with over 20 years experience as a practicing physician. He is the founder of both Satisfai Health and its ai4gi joint venture. He is a Clinical Professor of Medicine in the Division of Gastroenterology at Vancouver General Hospital and UBC. He is also director of the Interventional Endoscopy Fellowship at VGH, and is the former Director of Endoscopy at VGH/UBC.

He has worked in the medical device space for several years. Prior to his role with Satisfai Health and his participation in the ai4gi project, he has worked with the Biotechnology Industry in several areas including colon cancer genetic testing, and novel applications of Photodynamic therapy for Gastrointestinal disease.

He is a graduate of Cambridge and Liverpool Universities. He has a strong research background in both basic science and clinical medicine with hands-on training in molecular sciene and pharmacology. He received an MD by thesis from the University of Cambridge for his work on Helicobacter Pylori and Cyclooxygenase. He also has a long track record of clinical research. Dr. Byrne has published extensively with over 90 peer reviewed publications and over 100 abstract presentations at National and International Meetings.

After several years working in the UK and Ireland, Dr. Byrne completed an Interventional Endoscopy Fellowship as well as working as an attending physician at Duke University Medical Center, North Carolina. He moved to his current role in Vancouver in 2003.

His main clinical interests are in the field of ERCP, interventional endoscopy, optical biopsy, colon cancer, pancreaticobiliary disease, and IBD.